Transo-Pharm Epinephrine (Adrenaline) Approved in China

We are excited to share that our Epinephrine (Adrenaline) API has received DMF (Drug Master File) approval from the NMPA (National Medical Products Administration) in China. The approval (#Y20190000447) was officially published on the CDE (Center for Drug Evaluation) website on April 16, 2025.
With this important milestone, Transo-Pharm is ready to fully support clients planning to launch formulations containing our Epinephrine API in the Chinese market.
For more information or support, please contact our Product Manager, Jessica Ha, at [email protected].